ABSTRACT
Epithelial cell adhesion molecule EpCAM is strongly over-expressed in a variety of carcinomas where it is involved in signalling events resulting in increased expression of target genes such as c-Myc, cyclins and others, eventually conferring cells an oncogenic phenotype. However, EpCAM is also expressed in a series of healthy epithelia, albeit generally to a far lesser extend. We have uncovered differential glycosylation of EpCAM as a means to discriminate normal from malignant tissues. EpCAM was hyperglycosylated in carcinoma tissue as compared with autologous normal epithelia. All three N-glycosylation consensus sequences within EpCAM´s extracellular domain were used in human and murine cells. We show that glycosylation at asparagine 198 is crucial for protein stability. Mutants of EpCAM that substitute asparagine 198 for alanine showed a decreased overall expression and halflife of the molecule at the plasma membrane. This is of considerable importance with respect to EpCAM variants expressed in normal tissue, where it might reveal to be less stable and thus may have repercussions on functionality.
INTRODUCTION
Epithelial cell adhesion molecule EpCAM (CD326) is an integral trans-membrane protein whose overexpression is a signature of malignant tissue (1) and cancer stem cells (2) (3) (4) (5) . EpCAM acts as a homophilic adhesion molecule that localises to the basolateral membrane of normal cells, whereas it re-distributes all over the cell surface in carcinoma cells (6) . Over the last two decades an increasing number of publications and clinical trials underscored the importance of this molecule for diagnosis, prognosis, and therapy of carcinomas of different origins (1, (7) (8) (9) (10) . In more recent years research on EpCAM widened up so as to consider its molecular functions, too. Clearly, a sole function as a cell adhesion molecule does hardly explain its frequent and high-level over-expression in carcinomas. More compelling evidence, which profoundly changed the view on EpCAM, was the fact that EpCAM induces regulators of cell cycle transition such as the oncogenic transcription factor c-Myc and cyclins, along with a pronounced effect on cell proliferation upon de novo expression in epithelia (11) (12) (13) . Newest achievements in EpCAM research, clinical applications, and in the perception of it were lately reviewed in Baeuerle et al. (14) and Trzpis et al. (15) .
Although EpCAM is generally heavily overexpressed, and in some cases even de novo expressed in carcinoma, it necessarily must be perceived as a tumourassociated antigen that is also expressed in normal tissue (1, 7) . Hence, questions about differences in EpCAM functions in normal and tumour tissues consequently arise. In this respect a couple of scenarios come into mind: (i) the sole over-expression might allow for the overrun of a threshold of EpCAM expression required for oncogenic signalling; (ii) EpCAM may eventually encounter interaction partners in carcinoma cells that modify and switch its function such as to become oncogenic, and (iii) tumour-specific modifications might impact on EpCAM´s function. Obviously every scenario comes up with pros and cons. EpCAM is commonly over-expressed but then again it is likewise very strongly present at the cell surface of normal thyroid epithelia amongst others (16) . Hence, overexpression is certainly one but not the sole trigger for its phenotype in carcinoma cells. The knowledge on EpCAM interaction partners is unfortunately scarce with members of the tetraspanins (17), CD44 and claudins (18, 19) , and aactinin (20) being the only ones described as yet. Great hope is placed on these interacting proteins towards a refined view and understanding of EpCAM and its functions in health and disease. Tumour specific mutations have to our knowledge not been reported so far whilst a hyper-glycosylation of EpCAM in carcinoma versus normal epithelia was seen for the case of head and neck carcinoma (16) . A potential repercussion of such differential glycosylation is as yet entirely unexplored for EpCAM, albeit being an accepted fact for other cell surface molecules such as Notch (21, 22) , E-cadherin, integrins, and CD44 (23) . For this reason, we here analysed the impact of N-glycosylation on EpCAM with serial substitution mutants.
MATERIALS AND METHODS

Cell lines and primary samples
Human embryonical kidney cells HEK293 are adenovirus-transformed cells, which have an epithelial phenotyp (24) . NIH3T3 are murine fibroblasts (ATCC CRL-1658). All cell lines were propagated at 37°C in a 5% CO 2 -humidified incubator in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal calf serum (Biochrom AG, Berlin, Germany) and 100 U/ml penicillin, 100 µg/ml streptomycin. Cells were passaged twice a week by trypsin/EDTA treatment (all chemicals and supplements for cell culture were purchased from Biochrom AG, Berlin, Germany).
Flow cytometry, immunoblotting, glycostain, and glycosidase treatment
Non-permeabilised cells (5x10 5 ) were incubated with EpCAM-specific C215 antibody (kind gift of Dr. Horst Lindhofer, TrionPharma, Munich, Germany) for 1h 4°C, washed in PBS with 3% FCS, and stained with a FITC-labelled secondary antibody (30min, 4°C), and analyzed in a FACScalibur device (Becton/Dickinson, Heidelberg, Germany). For cycloheximide assay (CHX) cells were incubated with 10µM CHX for the indicated timepoints before analysed in a FACScalibur device as described above. For immunoblotting, cells (5x10 6 ) were lysed in 100µl buffer containing 1% triton X-100, complete protease cocktail (Roche Diagnostics, Mannheim, Germany) in tris-buffered saline (PBS). Lysates were precleared by centrifugation (13.000rpm, 15min, 4°C) and separated on a 10% SDS-PAGE. The detection of EpCAM was performed with the C215 antibody in combination with an HRP-conjugated secondary antibody and the ECL detection system (Amersham Biosciences, Freiburg, Germany). Whole cell lysate were treated with PNGaseF as recommended by the manufacturer (New England Biolabs). For glycostaining, EpCAM variants were transiently transfected into HEK293 cells and lysed in 1%-triton X-100 in PBS. After preclearing (13.000rpm, 4°C, 10min), lysates were immunoprecipitated with immobilised C215 monoclonal antibody. For this 5µg C215 were covalently coupled on protein G sepharose beads (GE-Healthcare) according to published protocols (25) . Cell lysates were incubated with immobilised EpCAM-specific antibodies over night at 4°C on a tumbler. Immunoprecipitates were sedimented upon centrifugation (1200rpm, RT, 10min), dissolved in Laemmli buffer (26) and separated on a 10% SDS-PAGE. Glycostaining was conducted with Pro-Q Emerald 488 glycoprotein gel and blot stain kit (Molecular Probes, Göttingen, Germany). Stained gels were recorded in a Fuji FLA5000 scanner device.
RESULTS
EpCAM N76/111A mutant is still glycosylated in eukaryotic cells
According to Chong et al., only two of the three consensus glycosylation motifs in the extracellular domain of EpCAM are used in insect cells. Asparagine at amino acid position 111 (N111) is reported to be fully glycosylated, while N76 is partially modified (27) . We generated two single mutants and a double mutant that exchanged both asparagine glycosylation sites for alanines. Wildtyp EpCAM, EpCAM N76A , EpCAM N111A , and EpCAM N76/111A expression vectors were transiently transfected into human embryonic kidney HEK293 cells and murine NIH3T3 fibroblasts. The expression of each EpCAM variant was assessed by immunoblotting 24hrs following transfection. Wild-type unglycosylated EpCAM molecule migrated at an estimated molecular weight (M r ) of 35kDa, while glycosylated variants displayed apparent M r of 40 and 42kDa ( Figure 1A , second lane). Although EpCAM N76A , EpCAM N111A , and EpCAM N76/111A mutations resulted in changes of the migration pattern, generating protein bands of lower M r , none of the three mutants displayed a phenotype of unglycosylated EpCAM, i.e. expectedly a single band of 35kDa ( Figure 1A) . In order to verify this issue, glycosylation of all four EpCAM variants was determined more specifically. EpCAM variants were transiently transfected into HEK293 cells and subsequently immunoprecipitated with the C215 monoclonal antibody. Thereafter, immunoprecipitates were separated on a standard SDS-PAGE and glycosylated proteins were Immunoprecipitates were separated on a 10% SDS-PAGE and glycosylated proteins revealed using the glycostain kit. E.) HEK293 transfectants harbouring the indicated EpCAM variants were subjected to treatment with PNFGase glycosidase. Thereafter, cell lysates were separated upon SDS-PAGE and EpCAM visualised with specific antibodies. Shown are the scanned images from three independent experiments. stained with Pro-Q Emerald 488 glycoprotein gel and staining kit. All EpCAM variants, including wild-type and mutants, showed glycosylated proteins of the expected size ( Figure 1B) . Thus, although mutation of asparagine 76 and 111 to alanine led to a changed glycosylation pattern, it did not abolish glycosylation entirely. These experiments suggested, that additional glycosylation sites are used in eukaryotic cells. The anchorage of O-glycosyl residues does not occur in the EpCAM molecule and can thus not account for the observed migration pattern of EpCAM mutants (16).
Mutation of asparagine 198 has a negative impact on protein stability
The findings described above prompted us to mutate the third glycosylation consensus sequence at asparagine amino acid position 198 to an alanine. Mutations were generated in the context of a single mutant (EpCAM N198A ) and a triple mutant (EpCAM N76/111/198A ). All EpCAM variants were transiently transfected into HEK293 cells. Expression patterns were analysed upon immunoblotting 24hrs after transfection. The striking finding was that mutation of asparagine 198 to an alanine resulted in a substantially decreased expression of EpCAM ( Figure 1C, lane 6 and 7) . Then again, although expressed to low extend the single asparagine 198 mutant of EpCAM was still to some degree glycosylated while the triple mutant EpCAM N76/111/198A was no longer modified as referring to the addition of glycosyl residues ( Figure 1D , lane 5 and 6). Treatment of cells with glycosidase unravelled that EpCAM N76/111/198A displayed migration properties similar to unglycosylated EpCAM ( Figure 1E ). Hence, unlike for the case of insect cells, in mammalian cells EpCAM is post-translationally modified at all Nglycosylation sites and asparagine 198 obviously warrants for protein stability. These data were further corroborated by similar findings in transfectants of murine NIH3T3 fibroblasts (data not shown). Based on this observation, we next stably expressed all EpCAM variants in HEK293 cells and measured cell surface expression by flow cytometry. As compared with EpCAMwt, mutation of asparagines 76/111 rather yielded variants with slightly enhanced cell surface expression, though only with significant p-value for the case of EpCAM N111A . As anticipated from immunoblot analysis, mutation of asparagine 198 to alanine resulted in a mean 55% decrease in cell surface expression for the case of the single as well as the triple mutant (Figure 2 ). This phenotype was reproduced in a set of individual bulk culture transfectants, thus excluding positioning effects after insertion of the plasmid into chromosomal DNA (data not shown).
In order to guaranty that the observed differences in expression across EpCAM mutants do not originate from disturbed transcription of the cognate messenger RNA, HEK293 stable transfectants were subjected to reverse transcription polymerase chain reaction (RT-PCR) amplification with EpCAM-specific primers. Although differences in mRNA levels became obvious, they pinpointed high levels of mRNA for aspargine 198 mutants ( Figure 3B ). So, reduced mRNA levels cannot account for the assessed differences in EpCAM expression of asparagine 198 mutants. Next, cell surface retention of EpCAM was monitored by flow cytometry following cycloheximid treatment of stable transfectants to interfere with novel protein synthesis. Cells were treated for 12hrs with cycloheximid, stained with EpCAM-specific antibody C215 that binds a discontinuous epitope within the far Nterminus (28) . Wild-type EpCAM displayed a calculated half-life of 21hrs at the cell surface. In sharp contrast, EpCAMN76/111/198A had a three-fold reduced half-life with a cell surface abidance of 7hrs ( Figure 3B ).
DISCUSSION
EpCAM is amongst the tumour-associated antigens most frequently overexpressed and for that reason a popular target in immunotherapy (7, 14) . In addition it is a valuable prognostic marker for a variety of carcinoma, which adds yet another facet to its multiple therapeutic value (8, 9, (29) (30) (31) (32) . However, EpCAM is not solely expressed on malignant tissue but on developing epithelia and some differentiated epithelia, too (15) (16) . EpCAM as expressed in normal tissue was hypo-whilst EpCAM derived from carcinoma samples was hyperglycosylated. In other words, N-glycosylation of EpCAM allowed for a sensitive discrimination of healthy and malignant epithelia of the upper aerodigestive tract.
More recent work on EpCAM´s function unravelled a capacity to induce cell proliferation, to foster nuclear signalling to enhance transcription of the c-myc proto-oncogene and eFABP, and to enhance enzymatic activities involved in the conversion of toxic intermediates of glycolysis (11) (12) (13) 33) . It is at present unclear whether and if so how differences in function of EpCAM in normal and malignant tissue are set. Regulation of signalling activity and of protein stability upon differential glycosylation is an accepted feature of membraneassociated receptors such as Notch and other regulators of cell fates and development (21, 22, 34, 35) . A control function was assigned early-on to glycosylation for the case of proteins of immune cells (36) and more recently to general processes in cancer development (37) (38) (39) . A long reputed antigen with differential glycosylation pattern in health and disease is the mucin-1 protein (MUC-1) that is hypoglycosylated in tumours as compared with normal mucosa (40) (41) , which is eventually the opposite case to EpCAM (16) . As shown in the present work, hyperglycosylation at asparagine 198 has a strong impact on EpCAM. It efficiently increases EpCAM´s stability and cell surface retention with a half-life at the plasma membrane of twenty-one hours versus seven hours for EpCAM wt and EpCAM N76/111/198A, respectively. Hence, two notions emerge. Firstly, asparagine 198 is in use in mammalian cells, which is not the case for insect cells (27) . Secondly, 198 is not only used but, more importantly, it reveals instrumental with respect to EpCAM stability as substitution of it reduced EpCAM stability to one third of the wild-typ protein. With this notion in mind it is tempting to speculate that the strength of EpCAM signalling may be controlled partly over its glycosylation at this precise amino acid residue. With carcinoma-derived EpCAM being heavily glycosylated, this may result in a molecule with improved cell surface presence and hence enhanced signalling capacity. Oppositely, EpCAM as expressed on normal epithelia may be prone to more rapid turn-over and be less signalling active. Eventually, the strength and duration of EpCAM signalling may dictate cellular outcome. Additionally, the availability of cellular ligands for EpCAM will predict signal intensity or even onset. A reflection of it was recently published as it was demonstrated that claudin 7 and CD44 variants in a complex with EpCAM promote colon cancer progression (19) .
Finally, it seems highly interesting to assess glycosylation patterns in normal, developing, and malignant tissue so as to decipher potential differences that may translate into selective EpCAM functions.
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